AUTHOR=Wang Shuai , Lin Xiaoxiao , Guan Yihong , Huang Jinyu 

TITLE=The clinical outcomes of reni-angiotensin system inhibitors for patients after transcatheter aortic valve replacement: A systematic review and meta-analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.963731

DOI=10.3389/fcvm.2022.963731

ISSN=2297-055X

ABSTRACT=<sec><title>Aims</title><p>The objective of our systematic reviews and meta-analysis is to evaluate the clinical outcomes of RAS inhibitors for patients after TAVR.</p></sec><sec><title>Methods and results</title><p>We performed a comprehensive search for Embase, Pubmed, and Cochrane databases from inception to May 1, 2022. The analysis of all outcomes was performed using the random-effects model. In total, 7 articles with a total of 32,585 patients (RAS inhibitor, <italic>N</italic> = 14,871; Controls, <italic>N</italic> = 17,714) were included in our study. There was a significantly lower rates of all-cause mortality (RR = 0.76, 95%Cl = 0.68 to 0.86, <italic>P</italic> &lt; 0.01), cardiovascular death (RR = 0.66, 95%Cl = 0.59–0.74, <italic>P</italic> &lt; 0.01) and HF readmission (RR = 0.87, 95%Cl = 0.80–0.94, <italic>P</italic> &lt; 0.01) in patients with RAS inhibitors compared with controls. Patients with RAS inhibitors also had lower rates of all-cause mortality (RR = 0.82, 95%Cl = 0.76–0.89, <italic>P</italic> &lt; 0.01) and cardiovascular death (RR = 0.73, 95%Cl, 0.62–0.85, <italic>P</italic> &lt; 0.01) after propensity matching.</p></sec><sec><title>Conclusions</title><p>In conclusion, our systematic reviews and meta-analysis demonstrated that RAS inhibitors could improve the clinical outcomes for patients after TAVR. Further large and high-quality trials should be conducted to support the use of RAS inhibitors for patients after TAVR.</p></sec>